Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with Stonegate Capital Partners Inc. ("Stonegate") based in Dallas, Texas. Under the terms of the agreement Stonegate will receive a monthly fee of $4,000 for a minimum of 6 months and will be granted 24,000 options. Such options will vest quarterly starting on the date of the grant, will be exercisable at a price of $0.52, and will expire October 31, 2017.

About Stonegate Capital Partners

Stonegate Capital Partners is an investment banking and corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. They provide research, sales and trading, corporate finance, strategic advisory and corporate advisor services to a select group of clients. They work with leading institutional investors in the U.S. and Europe who seek high quality investment opportunities in the small cap marketplace.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for severe acute pain.

www.antibethera.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Important Note on Forward Looking Statements

Copyright Business Wire 2010